Sofosbuvir/velpatasvir

Property	Value
rdf:type	World Health Organization essential medicine owl:NamedIndividual Combination drug NS5A inhibitor Drug granted breakthrough therapy designation NS5B (polymerase) inhibitor
rdfs:label	Sofosbuvir/velpatasvir
owl:sameAs	dbr:Sofosbuvir/velpatasvir
prov:wasDerivedFrom	http://en.wikipedia.org/wiki/Category:NS5A_inhibitors http://en.wikipedia.org/wiki/Category:NS5B_(polymerase)_inhibitors http://en.wikipedia.org/wiki/Category:World_Health_Organization_essential_medicines http://en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines http://en.wikipedia.org/wiki/Category:Combination_drugs http://en.wikipedia.org/wiki/List_of_drugs_granted_breakthrough_therapy_designation
skos:prefLabel	Sofosbuvir/velpatasvir
skos:altLabel	Sofosbuvir and velpatasvir Sofosbuvir/Velpatasvir combination with sofosbuvir sofosbuvir/velpatasvir
clgo:alternativeName	Epclusa, Sofosvel, Velpanat, others
clgo:casNumber	1190307-88-0 1377049-84-7
clgo:fdaUniiCode	KCU0C7RS7Z WJ6CA3ZU8B
clgo:kegg	D10827
clgo:medlinePlus	a616034
clgo:pubchem	91885554
is clgo:product of	Gilead Sciences Beacon Pharmaceuticals

About: clgr:Sofosbuvir/velpatasvir